Healthcare > Pharmaceuticals & Biotechnology
•2432 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2432)
| Company | Market Cap | Price |
|---|---|---|
|
CPIX
Cumberland Pharmaceuticals Inc.
Caldolor is a non-opioid IV analgesic, aligning CPIX with non-opioid pain management products.
|
$69.56M |
$4.68
-1.68%
|
|
ATYR
aTyr Pharma, Inc.
Efzofitimod is a biologic immunomodulator addressing inflammation in ILD, aligning with Immunology Therapeutics.
|
$69.43M |
$0.71
+0.03%
|
|
BYSI
BeyondSpring Inc.
BeyondSpring develops oncology therapeutics (Plinabulin) with a novel SIMBA mechanism, directly addressing cancer and CIN.
|
$68.97M |
$1.76
-0.56%
|
|
EUDA
EUDA Health Holdings Limited
EUDA's core biotech activity is a stem cell platform and cell therapy development using iPSCs.
|
$68.73M |
$1.88
+2.46%
|
|
VRCA
Verrica Pharmaceuticals Inc.
VP-315 is a peptide therapeutic for basal cell carcinoma, a clear major pipeline asset.
|
$68.58M |
$7.32
-3.81%
|
|
IMUX
Immunic, Inc.
Immunic's lead programs are oral, small-molecule therapeutics (e.g., vidofludimus calcium and IMU-856).
|
$68.07M |
$0.69
+0.07%
|
|
IFRX
InflaRx N.V.
Vilobelimab is an anti-C5a monoclonal antibody, making InflaRx's core product line Monoclonal Antibody Therapeutics.
|
$67.75M |
$1.02
+2.00%
|
|
CRVO
CervoMed Inc.
Neflamapimod is an orally administered, small-molecule therapeutic, aligning with the 'Oral Small Molecule Therapeutics' category.
|
$67.36M |
$7.30
+3.18%
|
|
PMVP
PMV Pharmaceuticals, Inc.
PMVP is a biotech company focused on oncology, developing rezatapopt to restore p53 function in TP53-mutant cancers, representing its core product category.
|
$66.77M |
$1.25
-0.40%
|
|
COEP
Coeptis Therapeutics, Inc.
GEAR Cell Therapy Platform is a core cell therapy biotech asset.
|
$66.45M |
$13.18
-3.48%
|
|
ANL
Adlai Nortye Ltd.
Adlai Nortye is a clinical-stage biotechnology company focused on oncology therapies, establishing Biotech - Oncology as its core domain.
|
$66.35M |
$1.66
-1.19%
|
|
TVGN
Tevogen Bio Holdings Inc.
ExacTcell off-the-shelf T cell therapies and the TVGN 489 program position Tevogen as a cell therapy biotech focused on oncology and infectious disease.
|
$66.11M |
$0.34
+2.73%
|
|
MGX
Metagenomi, Inc. Common Stock
MGX's core platform is gene therapy/gene editing tools enabling therapeutic gene modification, including in vivo MGX-1.00 programs.
|
$65.31M |
$1.78
+2.30%
|
|
AKYA
Akoya Biosciences, Inc.
Engagement in companion diagnostics through clinical collaborations (e.g., Acrivon, NeraCare).
|
$64.26M |
$1.29
|
|
RFL
Rafael Holdings, Inc.
NPC1 rare-disease program (Trappsol Cyclo) places Rafael Holdings in the Biotech - Rare Diseases category.
|
$64.20M |
$1.24
|
|
TCRX
TScan Therapeutics, Inc.
Directly related to cell therapy products (TCR-T therapies) and platform-enabled manufacturing via ImmunoBank/T-Plex.
|
$64.13M |
$1.15
+0.88%
|
|
ALXO
ALX Oncology Holdings Inc.
ALX Oncology explicitly focuses on cancer therapies (immuno-oncology), placing it under Biotech - Oncology.
|
$62.65M |
$1.18
-2.89%
|
|
LPCN
Lipocine Inc.
Lipocine leverages the proprietary Lipral drug delivery platform, a core asset that enables oral delivery of challenging molecules and underpins its product candidates.
|
$60.31M |
$11.17
-0.80%
|
|
DRRX
DURECT Corporation
Larsucosterol is described as an orally bioavailable small molecule therapeutic and the lead program for DURECT, targeting alcohol-associated hepatitis.
|
$59.29M |
$1.91
|
|
BDSX
Biodesix, Inc.
Biodesix's Development Services revenue aligns with CRO-like outsourced diagnostic testing for partners.
|
$57.77M |
$7.89
-5.22%
|
|
ICCC
ImmuCell Corporation
The company develops immunology-based therapeutics for animal health, including passive immunity and antimicrobial approaches used in calves and dairy cows.
|
$57.44M |
$6.25
-1.50%
|
|
KPTI
Karyopharm Therapeutics Inc.
Karyopharm's core business is oncology-focused biotechnology/pharmaceuticals, including the approved cancer therapy XPOVIO (selinexor) and an oncology pipeline.
|
$54.72M |
$6.29
-5.56%
|
|
INKT
MiNK Therapeutics, Inc.
MiNK's lead product agenT-797 and pipeline comprise allogeneic, off-the-shelf iNKT cell therapies, a direct Cell Therapy business.
|
$54.09M |
$11.81
-0.17%
|
|
KRON
Kronos Bio, Inc.
Kronos Bio's core activity is oncology-focused biotechnology with a pipeline of small-molecule oncology agents, fitting Biotech - Oncology.
|
$53.65M |
$0.88
|
|
NTRB
Nutriband Inc.
Direct AVERSA drug-delivery platform enabling abuse-deterrent transdermal patches (lead product AVERSA Fentanyl) and related patch technologies.
|
$52.47M |
$4.44
+1.60%
|
|
PYPD
PolyPid Ltd.
D-PLEX100 leverages PolyPid's PLEX drug-delivery platform to provide localized, prolonged antibiotic release at the surgical site.
|
$51.35M |
$4.38
-0.34%
|
|
GRCE
Grace Therapeutics, Inc.
The company emphasizes proprietary drug-delivery platforms to reformulate existing compounds, a clear fit for 'Drug Delivery Platforms'.
|
$50.47M |
$3.67
+0.69%
|
|
ALGS
Aligos Therapeutics, Inc.
Aligos develops oral small-molecule therapeutics across its pipeline (HBV CAM-E, THR-β agonist, and pan-coronavirus protease inhibitor).
|
$48.84M |
$7.94
-3.87%
|
|
DTIL
Precision BioSciences, Inc.
ARCUS is Precision BioSciences' in vivo gene editing platform and the lead programs PBGENE-HBV and PBGENE-DMD are built on this technology for therapeutic gene edits.
|
$47.74M |
$4.08
+4.49%
|
|
ABVC
ABVC BioPharma, Inc.
ABVC's pipeline includes oncology therapeutics derived from plant compounds and cancer-focused programs.
|
$47.55M |
$2.04
-0.49%
|
|
OSTX
OS Therapies Incorporated
OSTX's lead therapy OST-HER2 is a cancer immunotherapy targeting oncology indications.
|
$46.56M |
$1.47
+0.34%
|
|
INMB
INmune Bio, Inc.
Directly represents INmune Bio's Alzheimer's disease therapeutics focus under the XPro DN-TNF program.
|
$45.99M |
$1.74
+6.75%
|
|
COSG
Cosmos Group Holdings Inc.
Cana Laboratories' facility upgrades and a 5-year Pharmex contract manufacturing agreement indicate COSG's direct contract manufacturing service in pharma.
|
$45.86M |
$0.00
|
Showing page 18 of 25 (2432 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
